RU2020111554A - Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген - Google Patents
Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген Download PDFInfo
- Publication number
- RU2020111554A RU2020111554A RU2020111554A RU2020111554A RU2020111554A RU 2020111554 A RU2020111554 A RU 2020111554A RU 2020111554 A RU2020111554 A RU 2020111554A RU 2020111554 A RU2020111554 A RU 2020111554A RU 2020111554 A RU2020111554 A RU 2020111554A
- Authority
- RU
- Russia
- Prior art keywords
- antigen binding
- seq
- chain variable
- variable domain
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549201P | 2017-08-23 | 2017-08-23 | |
| US62/549,201 | 2017-08-23 | ||
| US201762558511P | 2017-09-14 | 2017-09-14 | |
| US201762558510P | 2017-09-14 | 2017-09-14 | |
| US201762558514P | 2017-09-14 | 2017-09-14 | |
| US201762558509P | 2017-09-14 | 2017-09-14 | |
| US62/558,511 | 2017-09-14 | ||
| US62/558,514 | 2017-09-14 | ||
| US62/558,510 | 2017-09-14 | ||
| US62/558,509 | 2017-09-14 | ||
| US201762566828P | 2017-10-02 | 2017-10-02 | |
| US62/566,828 | 2017-10-02 | ||
| US201762581357P | 2017-11-03 | 2017-11-03 | |
| US62/581,357 | 2017-11-03 | ||
| US201762608384P | 2017-12-20 | 2017-12-20 | |
| US62/608,384 | 2017-12-20 | ||
| PCT/US2018/047714 WO2019040727A1 (en) | 2017-08-23 | 2018-08-23 | BINDING PROTEINS FOR NKG2D, CD16 AND ANTIGEN ASSOCIATED WITH A TUMOR |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020111554A true RU2020111554A (ru) | 2021-09-23 |
| RU2020111554A3 RU2020111554A3 (https=) | 2022-01-19 |
Family
ID=65439284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020111554A RU2020111554A (ru) | 2017-08-23 | 2018-08-23 | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200231679A1 (https=) |
| EP (1) | EP3672993A4 (https=) |
| JP (2) | JP2020531525A (https=) |
| KR (1) | KR20200038530A (https=) |
| CN (1) | CN111315778A (https=) |
| AU (1) | AU2018322178A1 (https=) |
| BR (1) | BR112020003654A2 (https=) |
| CA (1) | CA3072919A1 (https=) |
| IL (2) | IL311488A (https=) |
| MX (1) | MX2020002036A (https=) |
| RU (1) | RU2020111554A (https=) |
| SG (1) | SG11201913968VA (https=) |
| WO (1) | WO2019040727A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| PE20221316A1 (es) * | 2019-10-15 | 2022-09-07 | Dragonfly Therapeutics Inc | Proteinas que se unen a nkg2d, cd16 y flt3 |
| US20230073946A1 (en) * | 2020-01-20 | 2023-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Affinity peptide conjugated with antioxidant for protection of proteins from oxidation |
| JP7512394B2 (ja) * | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| CN114437214B (zh) * | 2020-11-03 | 2023-06-02 | 南京北恒生物科技有限公司 | 靶向lir1的抗体及其用途 |
| EP4273161A4 (en) * | 2020-12-31 | 2025-04-02 | Innovent Biologics (Suzhou) Co., Ltd. | Protein with heterodimeric antibody FC and manufacturing method therefor |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2025166146A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + ox40 targeting antibodies and uses thereof |
| WO2025166138A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + tslp targeting antibodies and uses thereof |
| CN118812708B (zh) * | 2024-06-28 | 2025-04-04 | 北京普利米特生物科技有限公司 | 抗il-33抗体或其抗原结合片段及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040038339A1 (en) * | 2000-03-24 | 2004-02-26 | Peter Kufer | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| WO2007044756A2 (en) * | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| NZ573646A (en) * | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| AU2008337517B2 (en) * | 2007-12-14 | 2014-06-26 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
| WO2010017103A2 (en) * | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| JP6594855B2 (ja) * | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
| DE102013019352A1 (de) * | 2013-11-13 | 2015-09-17 | Elke Pogge Von Strandmann | Tri-spezifische rekombinante Antikörperderivate zur Behandlung von malignen Erkrankungen durch Aktivierung einer NK-Zell-basierten Immunantwort |
| DK3241561T3 (da) * | 2014-03-05 | 2025-06-30 | Autolus Ltd | Konjugeret antistof eller bispecifik t-celle-engager, som selektivt binder enten tcr-beta konstant region 1 (trbc1) eller trbc2 |
| CA2973720A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| WO2016134371A2 (en) * | 2015-02-20 | 2016-08-25 | Ohio State Innovation Foundation | Bivalent antibody directed against nkg2d and tumor associated antigens |
| DK3313876T3 (da) * | 2015-06-23 | 2025-04-22 | Innate Pharma | Multispecifikke antigenbindende proteiner |
| US20180327499A1 (en) * | 2015-11-13 | 2018-11-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| WO2017124002A1 (en) * | 2016-01-13 | 2017-07-20 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| WO2018148447A1 (en) * | 2017-02-08 | 2018-08-16 | Adimab, Llc | Antibody heavy chain variable domains targeting the nkg2d receptor |
| CN110461361A (zh) * | 2017-02-10 | 2019-11-15 | 蜻蜓治疗公司 | 结合bcma、nkg2d和cd16的蛋白 |
-
2018
- 2018-08-23 US US16/639,150 patent/US20200231679A1/en not_active Abandoned
- 2018-08-23 BR BR112020003654-4A patent/BR112020003654A2/pt not_active IP Right Cessation
- 2018-08-23 JP JP2020511319A patent/JP2020531525A/ja not_active Ceased
- 2018-08-23 AU AU2018322178A patent/AU2018322178A1/en not_active Abandoned
- 2018-08-23 IL IL311488A patent/IL311488A/en unknown
- 2018-08-23 EP EP18848423.2A patent/EP3672993A4/en not_active Withdrawn
- 2018-08-23 WO PCT/US2018/047714 patent/WO2019040727A1/en not_active Ceased
- 2018-08-23 KR KR1020207007908A patent/KR20200038530A/ko not_active Ceased
- 2018-08-23 MX MX2020002036A patent/MX2020002036A/es unknown
- 2018-08-23 SG SG11201913968VA patent/SG11201913968VA/en unknown
- 2018-08-23 RU RU2020111554A patent/RU2020111554A/ru unknown
- 2018-08-23 CA CA3072919A patent/CA3072919A1/en active Pending
- 2018-08-23 CN CN201880054953.2A patent/CN111315778A/zh active Pending
-
2020
- 2020-02-16 IL IL272706A patent/IL272706A/en unknown
-
2023
- 2023-02-24 JP JP2023027219A patent/JP2023062184A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019040727A1 (en) | 2019-02-28 |
| EP3672993A1 (en) | 2020-07-01 |
| US20200231679A1 (en) | 2020-07-23 |
| MX2020002036A (es) | 2020-03-24 |
| JP2023062184A (ja) | 2023-05-02 |
| JP2020531525A (ja) | 2020-11-05 |
| CA3072919A1 (en) | 2019-02-28 |
| BR112020003654A2 (pt) | 2020-11-17 |
| RU2020111554A3 (https=) | 2022-01-19 |
| IL272706A (en) | 2020-04-30 |
| AU2018322178A1 (en) | 2020-02-20 |
| EP3672993A4 (en) | 2021-10-27 |
| KR20200038530A (ko) | 2020-04-13 |
| IL311488A (en) | 2024-05-01 |
| SG11201913968VA (en) | 2020-01-30 |
| CN111315778A (zh) | 2020-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020111554A (ru) | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген | |
| JP2020531525A5 (https=) | ||
| Hosseini et al. | Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: recent advances and clinical trials | |
| JP6840682B2 (ja) | 多重特異的抗原結合タンパク質 | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| US20220135676A1 (en) | Multispecific antigen binding proteins | |
| JP6822849B2 (ja) | 多重特異的ＮＫｐ４６結合タンパク質 | |
| US20210024630A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| WO2019005641A1 (en) | GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF | |
| JP2020507328A5 (https=) | ||
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2020522473A5 (https=) | ||
| WO2015197582A1 (en) | Monomeric multispecific antigen binding proteins | |
| RU2021121771A (ru) | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19 | |
| US20200325232A1 (en) | Multispecific antigen binding proteins | |
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| RU2019128204A (ru) | Белки, связывающиеся с psma, nkg2d и cd16 | |
| Dhimolea et al. | World bispecific antibody summit, September 27–28, 2011, Boston, MA | |
| US20230279108A1 (en) | Therapeutic sirp-alpha antibodies | |
| Lutz et al. | Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells | |
| Dickopf et al. | Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi-or multispecific antibodies | |
| Schubert et al. | A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells | |
| EP4469478A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| CN121627890A (zh) | 包含nk细胞的药物组合物及其抑制癌细胞的用途 | |
| Blanco et al. | Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells |